Patents by Inventor Tohru Yamashita

Tohru Yamashita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compounds
    Patent number: 11939327
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: August 15, 2022
    Date of Patent: March 26, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tomoaki Hasui, Shinji Nakamura, Satoshi Mikami, Tohru Yamashita
  • HETEROCYCLIC COMPOUNDS
    Publication number: 20230278999
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: August 15, 2022
    Publication date: September 7, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tomoaki HASUI, Shinji NAKAMURA, Satoshi MIKAMI, Tohru YAMASHITA
  • Heterocyclic compounds
    Patent number: 11447488
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: September 20, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tomoaki Hasui, Shinji Nakamura, Satoshi Mikami, Tohru Yamashita
  • Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function
    Patent number: 11407748
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: August 9, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinji Nakamura, Satoshi Mikami, Tomoaki Hasui, Tohru Yamashita, Shinji Morimoto, Hidekazu Tokuhara, Norio Oyabu, Masami Yamada, Atsuko Ochida, Kazuaki Takami, Xin Liu
  • HETEROCYCLIC COMPOUND
    Publication number: 20200270243
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: October 4, 2018
    Publication date: August 27, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shinji NAKAMURA, Satoshi MIKAMI, Tomoaki HASUI, Tohru YAMASHITA, Shinji MORIMOTO, Hidekazu TOKUHARA, Norio OYABU, Masami YAMADA, Atsuko OCHIDA, Kazuaki TAKAMI, Xin LIU
  • HETEROCYLIC COMPOUNDS
    Publication number: 20200247801
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: October 4, 2018
    Publication date: August 6, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tomoaki Hasui, Shinji NAKAMURA, Satoshi MIKAMI, Tohru YAMASHITA
  • Tetrahydronaphthyridine somatostatin receptor 5 antagonists
    Patent number: 9751878
    Abstract: A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent for the prophylaxis or treatment of diabetes mellitus are provided.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: September 5, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Hideki Hirose, Takeshi Yamasaki, Tohru Yamashita, Asato Kina, Yoichi Nishikawa
  • Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
    Patent number: 9605000
    Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 28, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Masaki Ogino, Ryo Mizojiri, Takeshi Yamasaki, Hideki Hirose, Nobuyuki Takakura, Tohru Yamashita, Sachie Morimoto, Takashi Nakahata, Asato Kina
  • HETEROCYCLIC COMPOUNDS
    Publication number: 20160237087
    Abstract: A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent for the prophylaxis or treatment of diabetes mellitus are provided.
    Type: Application
    Filed: April 27, 2016
    Publication date: August 18, 2016
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Hideki Hirose, Takeshi Yamasaki, Tohru Yamashita, Asato Kina, Yoichi Nishikawa
  • Tetrahydronaphthyridine somatostatin receptor 5 antagonists
    Patent number: 9353108
    Abstract: A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent for the prophylaxis or treatment of diabetes mellitus are provided.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: May 31, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Hideki Hirose, Takeshi Yamasaki, Tohru Yamashita, Asato Kina
  • HETEROCYCLIC COMPOUND
    Publication number: 20160060273
    Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.
    Type: Application
    Filed: March 13, 2014
    Publication date: March 3, 2016
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo KASAI, Masaki OGINO, Ryo MIZOJIRI, Takeshi YAMASAKI, Hideki HIROSE, Nobuyuki TAKAKURA, Tohru YAMASHITA, Sachie MORIMOTO, Takashi NAKAHATA, Asato KINA
  • Bicyclic compound
    Patent number: 9133129
    Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: September 15, 2015
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tohru Yamashita, Takuya Fujimoto, Ryo Mizojiri, Kazuko Yonemori, Hideki Hirose, Zenichi Ikeda, Ikuo Fujimori, Kyoko Toyofuku, Tsuneo Yasuma, Nobuyuki Matsunaga
  • Heterocyclic compound
    Patent number: 9120777
    Abstract: A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent the prophylaxis or treatment of diabetes mellitus are provided.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: September 1, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Asato Kina, Hideki Hirose, Takeshi Yamasaki, Tohru Yamashita, Yoichi Nishikawa
  • HETEROCYCLIC COMPOUND
    Publication number: 20150119412
    Abstract: A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent the prophylaxis or treatment of diabetes mellitus are provided.
    Type: Application
    Filed: October 28, 2014
    Publication date: April 30, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Takashi Nakahata, Asato Kina, Hideki Hirose, Takeshi Yamasaki, Tohru Yamashita, Yoichi Nishikawa
  • HETEROCYCLIC COMPOUND
    Publication number: 20150099777
    Abstract: A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent for the prophylaxis or treatment of diabetes mellitus are provided.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Hideki Hirose, Takeshi Yamasaki, Tohru Yamashita, Asato Kina, Yoichi Nishikawa
  • BICYCLIC COMPOUND
    Publication number: 20140243310
    Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: October 23, 2012
    Publication date: August 28, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tohru Yamashita, Takuya Fujimoto, Ryo Mizojiri, Kazuko Yonemori, Hideki Hirose, Zenichi Ikeda, Ikuo Fujimori, Kyoko Toyofuku, Tsuneo Yasuma, Nobuyuki Matsunaga
  • Bicyclic compound
    Patent number: 8729102
    Abstract: The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes and the like, and having superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: May 20, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Yasuma, Tohru Yamashita, Takuya Fujimoto, Zenichi Ikeda
  • Bicyclic compound
    Patent number: 8703758
    Abstract: The present invention provides to a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: April 22, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tohru Yamashita, Makoto Kamata, Hideki Hirose, Masataka Murakami, Takuya Fujimoto, Zenichi Ikeda, Tsuneo Yasuma, Ikuo Fujimori, Ryo Mizojiri, Tomoya Yukawa
  • Bicyclic compound
    Patent number: 8501804
    Abstract: The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: August 6, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Makoto Kamata, Tohru Yamashita, Asato Kina, Michiko Amano
  • BICYCLIC COMPOUND
    Publication number: 20120142714
    Abstract: The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes and the like, and having superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: November 29, 2011
    Publication date: June 7, 2012
    Inventors: TSUNEO YASUMA, MAKOTO KAMATA, TOHRU YAMASHITA, HIDEKI HIROSE, MASATAKA MURAKAMI, ASATO KINA, KAZUKO YONEMORI, RYO MIZOJIRI, IKUO FUJIMORI, TAKUYA FUJIMOTO, ZENICHI IKEDA